Posted by Michael Wonder on 17 Jul 2023
FDA starts review of HLB's HCC drug rivoceranib
17 July 2023 - HLB said the US FDA has initiated a review for approving a combination therapy of rivoceranib and camrelizumab as the first-line treatment for hepatocellular carcinoma.
HLB Group Chairman Jin Yang-gon said on the company's YouTube account on Monday that its US subsidiary Elevar Therapeutics received the notification from the FDA at 10:30 p.m. last Friday.
